As part of his Ph.D. in pharmacy at Université Laval, Dr. Audet-Walsh focused on the link between steroid hormones and endometrial and prostate cancers. During his work, he has demonstrated that the regulation of steroid metabolism is altered in tumor cells, notably via alterations of specific metabolic pathways. In addition, several pharmacogenomic analyses have been able to establish the link between genetic markers in steroidogenesis genes in relationship with prostate cancer progression. He then undertook a postdoctoral fellowship at McGill University, where he studied transcriptional regulation mechanisms by members of the nuclear receptor family using transcriptomic, cistromic (functional genomic) and metabolomic tools in different in vitro and in vivo models, with a particular interest in the regulation of energy metabolism. Dr. Audet-Walsh has notably demonstrated the interaction between several nuclear receptors and different cell signaling pathways in the transcriptional control of cell metabolism following various stresses. In addition, he was interested in characterizing the different waves of transcriptional regulation that involve the functional interaction between different families of transcription factors, especially in hormone-sensitive cancers.

Recently recruited at the Centre de recherche du CHU de Québec – Laval University, Dr. Audet-Walsh specializes in the study of metabolic reprogramming in hormone-sensitive cancers, by nuclear receptors. By their actions, these receptors act as master regulators of the cellular bioenergetic pathways, necessary for both the synthesis of ATP and the biosynthesis of macromolecules that are essential to cell proliferation. By using transcriptomic, cistromic and metabolomic analyzes, he wants to understand how these receptors contribute to the transcriptional regulation of different cellular metabolic pathways in physiology and disease. In addition, he also wants to understand how metabolism in turn influences hormonal signaling, since several metabolic intermediates are essential for the regulation of the epigenome. Finally, a translational research approach targeting the key elements of metabolism in pathological conditions will be used to validate its results in a context of in vitro (cells in culture) and in vivo (rodent models, human samples) models. Understanding the metabolic reprogramming associated with pathological conditions, as well as the factors that control such reprogramming, will allow the identification of new therapeutic targets in different hormone-sensitive cancers.

CHUL
2705 Boulevard Laurier
R-4714
Ville de Québec, QC
Canada G1V 4G2
24 entries « 1 of 3 »

Gonthier K, Poluri RTK, Weidmann C, Tadros M, Audet-Walsh E

Reprogramming of Isocitrate Dehydrogenases Expression and Activity by the Androgen Receptor in Prostate Cancer.

Journal Article

Mol Cancer Res, 17 (8), pp. 1699-1709, 2019, ISSN: 1541-7786.

Abstract | Links:

Gonthier K, Poluri RTK, Audet-Walsh E

Functional genomic studies reveal the androgen receptor as a master regulator of cellular energy metabolism in prostate cancer.

Journal Article

J Steroid Biochem Mol Biol, 191 , pp. 105367, 2019, ISSN: 0960-0760.

Abstract | Links:

Poluri RTK, Audet-Walsh E

Genomic Deletion at 10q23 in Prostate Cancer: More Than PTEN Loss?

Journal Article

Front Oncol, 8 , pp. 246, 2018.

Abstract | Links:

Audet-Walsh E, Vernier M, Yee T, Laflamme C, Li S, Chen Y, Giguere V

SREBF1 Activity Is Regulated by an AR/mTOR Nuclear Axis in Prostate Cancer.

Journal Article

Mol Cancer Res, 16 (9), pp. 1396-1405, 2018, ISSN: 1541-7786.

Abstract | Links:

Audet-Walsh E, Dufour CR, Yee T, Zouanat FZ, Yan M, Kalloghlian G, Vernier M, Caron M, Bourque G, Scarlata E, Hamel L, Brimo F, Aprikian AG, Lapointe J, Chevalier S, Giguere V

Nuclear mTOR acts as a transcriptional integrator of the androgen signaling pathway in prostate cancer.

Journal Article

Genes Dev, 31 (12), pp. 1228-1242, 2017, ISSN: 0890-9369.

Abstract | Links:

Audet-Walsh E, Yee T, Tam IS, Giguere V

Inverse Regulation of DHT Synthesis Enzymes 5α-Reductase Types 1 and 2 by the Androgen Receptor in Prostate Cancer.

Journal Article

Endocrinology, 158 (4), pp. 1015-1021, 2017, ISSN: 0013-7227.

Abstract | Links:

Cornu JN, Audet-Walsh E, Drouin S, Bigot P, Valeri A, Fournier G, Azzouzi AR, Roupret M, Cormier L, Chanock S, Guillemette C, Cussenot O, Levesque E, Cancel-Tassin G

Correlation between prostate volume and single nucleotide polymorphisms implicated in the steroid pathway.

Journal Article

World J Urol, 35 (2), pp. 293-298, 2017, ISSN: 0724-4983.

Abstract | Links:

Audet-Walsh E, Yee T, McGuirk S, Vernier M, Ouellet C, St-Pierre J, Giguere V

Androgen-Dependent Repression of ERRγ Reprograms Metabolism in Prostate Cancer.

Journal Article

Cancer Res, 77 (2), pp. 378-389, 2017, ISSN: 0008-5472.

Abstract | Links:

Yan M, Audet-Walsh E, Manteghi S, Dufour CR, Walker B, Baba M, St-Pierre J, Giguere V, Pause A

Chronic AMPK activation via loss of FLCN induces functional beige adipose tissue through PGC-1α/ERRα.

Journal Article

Genes Dev, 30 (9), pp. 1034-46, 2016, ISSN: 0890-9369.

Abstract | Links:

Audet-Walsh E, Papadopoli DJ, Gravel SP, Yee T, Bridon G, Caron M, Bourque G, Giguere V, St-Pierre J

The PGC-1α/ERRα Axis Represses One-Carbon Metabolism and Promotes Sensitivity to Anti-folate Therapy in Breast Cancer.

Journal Article

Cell Rep, 14 (4), pp. 920-931, 2016.

Abstract | Links:

24 entries « 1 of 3 »
Signaler des ajouts ou des modifications

Active projects

  • Centre de recherche sur le cancer, Subvention, Institutionnel - BDR, BDR - Centres de recherche reconnus, from 1996-05-01 to 2023-04-30
  • Centres hospitaliers universitaires de Québec - Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
  • Deciphering the role of KLF5 and NFYA in prostate cancer, Subvention, Société de recherche sur le cancer, Subvention de fonctionnement, from 2018-09-01 to 2020-08-31
  • Functional interaction between the androgen and the estrogen signalling pathways in prostate cancer, Subvention, Instituts de recherche en santé du Canada, Subvention Projet, from 2018-10-01 to 2023-03-31
  • Génomique fonctionnelle des récepteurs aux hormones stéroïdiennes dans le contrôle du métabolisme énergétique des cellules de cancer de la prostate, Subvention, Fonds de recherche du Québec - Santé, Chercheur-boursier Juniors 1 et 2, Seniors, from 2019-07-01 to 2023-06-30
  • Regulation of Cellular Energy Metabolism in Mammary Epithelial Cells, Subvention, Conseil de recherches en sciences naturelles et génie Canada, Subventions à la découverte SD (individuelles et d'équipe), from 2019-04-01 to 2024-03-31
  • Regulation of Cellular Energy Metabolism in Mammary Epithelial Cells, Subvention, Conseil de recherches en sciences naturelles et génie Canada, Supplément Tremplin vers la découverte, from 2019-04-01 to 2020-03-31
  • Targeting the estrogen signaling pathway to treat prostate cancer, Subvention, American Association for Cancer Research, from 2018-12-01 to 2019-11-30

Recently finished projects

  • Chercheur boursier - Complément de salaire, Subvention, Université Laval - budget de fonctionnement, Compléments de salaire des professeurs sous octroi, from 2017-06-26 to 2018-04-30
  • Programme de soutien aux nouveaux professeurs de la Faculté de médecine, Subvention, Université Laval - démarrage nouveau chercheur, Soutien facultaire aux jeunes chercheurs de la Faculté de médecine, from 2017-07-01 to 2019-06-30
Data provided by the Université Laval research projects registery